Changes in mitochondrial stability during the progression of the Barrett’s esophagus disease sequence

N. J. O’Farrell1, R. Feighery1, S. L. Picardo1, N. Lynam-Lennon1, M. Biniecka2, S. A. McGarrigle1, J. J. Phelan1, F. MacCarthy3, D. O’Toole3, E. J. Fox4, N. Ravi1, J. V. Reynolds1 and J. O’Sullivan1

Abstract

Background: Barrett’s esophagus follows the classic step-wise progression of metaplasia-dysplasia-adenocarcinoma. While Barrett’s esophagus is a leading known risk factor for esophageal adenocarcinoma, the pathogenesis of this disease sequence is poorly understood. Mitochondria are highly susceptible to mutations due to high levels of reactive oxygen species (ROS) coupled with low levels of DNA repair. The timing and levels of mitochondria instability and dysfunction across the Barrett’s disease progression is under studied.

Methods: Using an in-vitro model representing the Barrett’s esophagus disease sequence of normal squamous epithelium (HET1A), metaplasia (QH), dysplasia (Go), and esophageal adenocarcinoma (OE33), random mitochondrial mutations, deletions and surrogate markers of mitochondrial function were assessed. In-vivo and ex-vivo tissues were also assessed for instability profiles.

Results: Barrett’s metaplastic cells demonstrated increased levels of ROS (p < 0.005) and increased levels of random mitochondrial mutations (p < 0.05) compared with all other stages of the Barrett’s disease sequence in-vitro. Using patient in-vivo samples, Barrett’s metaplasia tissue demonstrated significantly increased levels of random mitochondrial deletions (p = 0.043) compared with esophageal adenocarcinoma tissue, along with increased expression of cytoglobin (CYGB) (p < 0.05), a gene linked to oxidative stress, compared with all other points across the disease sequence. Using ex-vivo Barrett’s metaplastic and matched normal patient tissue explants, higher levels of cytochrome c (p = 0.003), SMAC/Diablo (p = 0.008) and four inflammatory cytokines (all p values <0.05) were secreted from Barrett’s metaplastic tissue compared with matched normal squamous epithelium.

Conclusions: We have demonstrated that increased mitochondrial instability and markers of cellular and mitochondrial stress are early events in the Barrett’s disease sequence.

Keywords: Barrett’s esophagus, Mitochondrial instability, Oxidative stress

Background

Esophageal cancer is one of the most rapidly increasing malignancies in the Western world [1]. Overall 5-year survival rates are low at approximately 14 % [2]. The last several decades have seen a change in the histological trend of this malignancy with adenocarcinoma now representing the leading sub-type in the West [3]. Barrett’s esophagus is a pathologic precursor of esophageal adenocarcinoma.

Following the classic metaplasia-dysplasia-adenocarcinoma sequence, it is speculated cancer development does not occur directly from non-dysplastic disease [4]. While Barrett’s esophagus follows this natural stepwise progression, the exact cellular instability mechanisms triggering cancer conversion are not fully elucidated.

The rate of mutagenesis in mitochondrial DNA is approximately 10-times higher than mutation rates in nuclear DNA. This is due to a combination of factors such as less proficient DNA repair mechanisms and high levels of exposure to ROS generated by the mitochondria themselves [5, 6]. The Warburg effect describes a
phenomenon of altered energy metabolism in cancer cells, with increased lactate production despite sufficient oxygen to power oxidative phosphorylation [7]. This state of aerobic glycolysis does not arise in normal functioning cells and it is speculated that cancer cells divert from normal energy pathways as a protective mechanism to promote cell survival [8, 9]. These factors of increased susceptibility to DNA injury, along with evidence of altered energy metabolism in the cancer setting, have highlighted the potential role of the mitochondria in human cancer development [10–12].

To date, research has primarily focussed on clonal mitochondrial mutations in relation to esophageal cancer [13]. Little work has explored the role of random mitochondrial point mutations as a trigger for Barrett’s cancer development. With each cell containing hundreds of mitochondria and correspondingly thousands of strands of the mitochondrial genome, it is possible for wild type and mutated mitochondrial DNA to co-exist [12]. It is hypothesized that during tumor development cancer cells exhibit a mutator phenotype, with higher frequencies of random mutations, which are not supported by the normal rates of mutagenesis seen in non-cancerous cells [14]. The mutator phenotype hypothesis proposes that cancer cells must incur increased rates of mutagenesis during disease progression [14, 15], and as such, this theory suggests that benign tumors with low levels of random mutations will not progress to malignancy. Lee et al. [16] have demonstrated significantly increased random mitochondrial mutations in Barrett’s specialized intestinal metaplasia (SIM) compared with adjacent normal tissue. It was hypothesized that instability within the mitochondria play a crucial role in Barrett’s cancer development, however, profiling these changes along the Barrett’s disease sequence remain largely unexplored.

With respect to Barrett’s esophagus, with less than 0.12 % of cases per year progressing to esophageal adenocarcinoma [17], it is prudent that we understand the early instability mechanisms involved in the cancer switch. The purpose of this study was to identify changes in mitochondrial mutation rates and function along the Barrett’s disease sequence using in-vitro, in-vivo and ex-vivo models.

Methods

In-vitro cell line sequence

Four esophageal cell lines were used; HET1A, QH, Go and OE33 cells representing the normal squamous epithelium-SIM-high grade dysplasia (HGD)-esophageal adenocarcinoma (EAC) sequence, respectively. HET1A cells were obtained from American Type Culture Collection (ATCC) (LGC Standards, Middlesex, UK), and maintained in antibiotic-free bronchial epithelial cell basal media (BEBM) enhanced with hormonal cocktail BEGM® SingleQuots®. QH and Go cells were obtained from ATCC and cultured in BEBM enhanced with BEGM® SingleQuots® and supplemented with 10 % foetal calf serum (FCS) (Lonza, MD, USA) and 1 % penicillin/streptomycin (Lonza). OE33 esophageal adenocarcinoma cells were sourced from the European Collection of Cell Cultures (Sailsbury, UK) and maintained in Roswell Park Memorial Institute (RPMI) 1640 medium (Lonza) supplemented with 10 % FCS and 1 % penicillin/streptomycin. All cell lines were maintained at 37 °C.

Mitochondrial random mutation capture (RMC) assay in cell lines and patient tissue

All research was carried out in accordance with the Declaration of Helsinki, with all patients providing informed written consent, and approval for this study was granted by the St James’s Hospital and Adelaide, Meath and National Children’s Hospital Institutional Review Board. In vivo patient samples were snap frozen in liquid nitrogen and stored at –80 ºC for RMC assay experiments. Patients with histologically confirmed SIM and Barrett’s-associated EAC were recruited while in attendance of Barrett’s esophagus surveillance endoscopy or esophagectomy at the National Esophageal and Gastric Centre at St. James’s Hospital, Dublin. In-vitro, HET1A, QH, Go and OE33 cells, of similar cell passage number were grown to 70–80 % confluence in 25 cm² flasks to isolate DNA for the RMC assay. In order to examine mitochondrial instability, random mitochondrial point mutations and deletions were quantified using detailed methods previously published by our group [18]. This RMC assay allows the quantification of point mutations and deletions in the mitochondrial genome at single molecule resolution. All tissues were analyzed in a blinded fashion. All PCR products were sequenced by the High-Throughput Sequencing Facility at the University of Washington.

Evaluation of mitochondrial function using mitochondrial assays for reactive oxygen species (ROS)

To further examine mitochondrial biology, ROS levels were examined in vitro. Cells were seeded in 96 well plates at density 2500 to 8000 cells/well, depending on the cell line. Seeding at different concentrations was necessary to compensate for different growth rates between different cell lines, in order to ensure the same degree of confluence at the initiation of functional experiments. Following 24 h, ROS levels were assessed. Cells were incubated with 5 μM 2′, 7-dichlorofluorescein diacetate (Sigma-Aldrich) using our previously published protocols [18]. Following 40 min incubation, the ROS probe was removed, cells were analyzed using the Spectra Max Gemini System at excitation 485 nm and emission 538 nm. Mean fluorescence values for each cell line were obtained from at least three independent experiments. Crystal violet
spectrophotometrically using a Nanodrop 1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE) and quality assessment of all samples was performed on the Agilent 2100 bioanalyzer platform (Agilent technologies, Santa Clara, CA), using the RNA Nano 6000 kit. High quality total RNA was reverse transcribed to cDNA using random hexamer oligodeoxyribonucleotides that prime mRNA for cDNA synthesis. Quantitative PCR was used to quantify cytoglobin mRNA expression (ABI Biosystems) in samples relative to the 18S ribosomal RNA endogenous control and analyzed using SDS 2.3 and SDS RQ Manager 1.2 relative quantification software. Analysis of gene expression data was performed using the 2\(^{ΔΔCt}\) relative quantification method using the change in the expression of a target gene relative to the expression of a reference sample in the study.

Measurement of secreted mitochondrial proteins and inflammatory cytokines from ex-vivo Barrett’s and matched normal explant tissue

Barrett’s esophagus patients’ biopsies (n = 12), from areas of SIM and surrounding normal tissue, were obtained for fresh ex-vivo explant culture at 37 °C. Matched-normal tissue biopsies were taken ≥ 5 cm from the most proximal border of macroscopic Barrett’s. Biopsies were immediately placed on saline-soaked gauze and transported within 10 min to the laboratory for ex-vivo culture 24-well plates containing 1 mL of M199 media (Lonza) supplemented with 10 % FCS, 1 % penicillin/streptomycin and 1 μg/ml insulin. Tissues were cultured for 24 h, and conditioned media stored at −80 °C. Barrett’s tissue was characterized by examining for the expression of the columnar epithelium molecular markers cytokeratin 8 and villin (Metabion). Tissue viability following explant culture was confirmed using a lactate dehydrogenase (LDH) assay (Caymanchem, Michigan, USA). Secretions of surrogate mitochondrial proteins, cytochrome c and SMAC/Diablo were measured in explant conditioned media using commercially available enzyme-linked immunosorbent assay (ELISA) kits (R&D Systems) using protocols as per manufacturers’ instructions. The levels of cytokines interleukin-8 (IL-8), interleukin-6 (IL-6), interleukin-1β (IL-1β) and tumour necrosis factor-α (TNF-α) were measured using a multiplex assay from Mesoscale Discovery® (Gaithersburg, MD, USA) using protocols as per manufactures’ instructions.

Statistical analysis

Data were analyzed with SPSS (PASW [Predictive Analytics Software] version 18) (IBM, Armonk, New York, USA) and Graph Pad Prism (Graph Pad Prism, San Diego, CA) software. Differences between HET1A, QH, Go and OE33 cell lines were calculated using unpaired Student’s t-tests and Kruskal Wallis tests. In-vitro results
were reported as mean and variation was expressed as standard deviation (SD). In-vivo and ex-vivo: differences between continuous variables, for matched patient groups were calculated using Wilcoxon signed-rank tests, while in unmatched patient groups the Mann–Whitney U test was used. Patient data were reported as mean and variation was expressed as standard error of the mean (SEM = SD divided by the square root of the sample size). Statistical significance was defined as \( p \leq 0.05 \).

**Results**

### Mitochondrial instability levels in the Barrett’s disease model

**In-vitro cell line assessment**

Significantly elevated random mitochondrial point mutations were an early event in the Barrett’s in-vitro model (Fig. 1). Levels of random mitochondrial point mutations were significantly increased in the QH, metaplastic cells, compared to the HET1A cells (\( p = 0.024 \)), Go cells (\( p = 0.008 \)) and OE33 cells (\( p = 0.006 \)). No significant difference was demonstrated in the frequency of random mitochondrial mutations between the HET1A, Go and OE33 cell lines (all \( p \) values >0.05). Levels of mitochondrial deletions were not evident in-vitro.

**In-vivo patient tissue assessment**

While there were no differences in the frequency of random mutations between SIM (mean = \( 8.269 \times 10^{-5} \), SEM = \( 2.223 \times 10^{-5} \)) and HGD/EAC tissue (mean = \( 7.422 \times 10^{-5} \), SEM = \( 1.615 \times 10^{-5} \) (\( p = 1.00 \)) (data not shown), interestingly, random mitochondrial deletions were significantly increased in SIM tissue (mean = \( 1.322 \times 10^{-5} \), SEM = \( 5.400 \times 10^{-6} \)) compared with HGD/EAC (mean = \( 2.63 \times 10^{-6} \), SEM = \( 1.250 \times 10^{-6} \) (\( p = 0.043 \)) (Fig. 2). Random deletions were significantly increased in SIM matched-normal tissue (mean = \( 2.983 \times 10^{-5} \), SEM = \( 1.178 \times 10^{-5} \)) compared with SIM biopsies (\( p = 0.031 \)) (Fig. 2). While not significant, there was a trend towards increased mitochondrial deletions in matched-normal tissue (mean = \( 1.652 \times 10^{-5} \), SEM = \( 2.331 \times 10^{-6} \)) compared with HGD/EAC cancerous tissue (\( p = 0.063 \).

**In-vitro Reactive Oxygen Species (ROS) assessment**

There was a 4.2-fold increase in ROS in the QH cells (mean 449.77, SD 26.848) (\( p < 0.0001 \)), a 3.2-fold increase in the Go cells (mean 346.4, SD 48.262) (\( p < 0.0001 \)) and a 2.6-fold increase in the OE33 cells (mean 276.826, SD 23.188) (\( p < 0.0001 \)) relative to the HET1As (mean 108.239, SD14.875). ROS levels were significantly higher in the QH cells compared with all other points in the Barrett’s cell line progression model (Fig. 3).

---

**Fig. 1** Random mitochondrial point mutations in-vitro. There was a significantly increased frequency of random mitochondrial DNA mutations in the QH cells (mean \( 7.710 \times 10^{-5} \), SD \( 2.770 \times 10^{-5} \) (\( n = 5 \)) compared to HET1A (mean \( 2.560 \times 10^{-5} \), SD \( 1.015 \times 10^{-5} \) (\( n = 3 \)), Go (mean \( 2.730 \times 10^{-5} \), SD \( 2.440 \times 10^{-5} \) (\( n = 5 \)) and OE33 (mean \( 2.500 \times 10^{-5} \), SD \( 1.430 \times 10^{-5} \) (\( n = 5 \)) cells. This demonstrated that random mutations were an early event in this in-vitro model of Barrett’s progression. *\( p \leq 0.05 \)
Cytoglobin (CYGB) gene expression levels across the Barrett’s disease progression model

There was a 25.9-fold increase in CYGB expression in SIM (mean 11.013, SEM 8.493) compared with normal biopsies (mean 0.425, SEM 0.231) \((p=0.013)\). Levels of CYGB was significantly increased in SIM cases compared to LGD (mean 6.03, SEM 1.555) \((p=0.010)\) and EAC (mean 4.581, SEM 0.991) \((p=0.022)\) (Fig. 4).

Ex-vivo secretions of mitochondrial proteins and inflammatory cytokines from Barrett’s and matched normal explants

Secreted cytochrome c and SMAC/Diablo were significantly higher from SIM tissue compared with matched normal tissue \((p=0.003, p=0.008\) respectively) (Fig. 5a, b). Inflammatory cytokines were also significantly increased in SIM tissue compared with matched normal tissue; IL-1β \((p=0.007)\), IL-6 \((p=0.0005)\), IL-8 \((p=0.002)\) and TNF-α \((p=0.034)\) (Fig. 5c-f).

Discussion

The role of mitochondrial instability in the progression of Barrett’s esophagus is poorly understood. Metabolic imbalances, such as reduced response to apoptosis and increased glycolysis are all features of cancer cells, and are tightly regulated by the mitochondria \([11, 23, 24]\). Mutagenesis is a catalyst for cancer development, but to date, clonal gene mutations have been the main type of mitochondrial mutations analyzed with respect to esophageal carcinoma. The mitochondrial genome is more vulnerable to random mutations due to high ROS exposure and lower DNA repair mechanisms compared with nuclear DNA \([5, 25]\). Here we examined alterations in random mitochondrial point mutations/deletions and other markers of mitochondrial instability in the Barrett’s esophagus disease sequence using in-vitro, in-vivo and ex-vivo models.
Using an in-vitro cell line model, we demonstrated random mitochondrial mutations were significantly elevated in the metaplastic, QH, cells compared with all other points along the Barrett’s disease sequence, represented by the different cell lines. During tumor development, cancer cells are understood to exhibit a mutator phenotype with increased rates of mutagenesis during disease progression [14, 15, 26–28]. In this theory, benign tumors with low levels of random defects will not progress to malignancy, and the mutator frequency will influence risk. In other studies, increased random mitochondrial mutations have been reported in SIM compared with adjacent normal tissue [16]. In our study, using the RMC assay, mitochondrial deletions, a form of rearrangement of the mitochondrial genome and a recognized marker of mitochondrial instability [29], were significantly increased in SIM compared with HGD/EAC. An increased frequency of deletions in SIM compared with HGD/EAC is mirrored in colorectal polyp/cancer studies [30], both supporting the hypothesis that random mutations/deletions may become redundant as the disease progresses. It is recognized once malignant cells become established, selection processes ensue, with more aggressive mutations surviving and undergoing subsequent replication, with clonal mutations/deletions and not random ones overtaking the initial catalyst for cancer development at this time in the disease sequence [15, 31].

In this study, surrounding normal tissue demonstrated increased deletions compared with areas of SIM or HGD/EAC, suggesting mitochondrial instability is not just confined to the visible site of pathological tissue abnormality in the esophagus with Barrett’s disease, but exerts a field effect, which has been previously demonstrated in colorectal tumors [30].

The changes in the mitochondrial environment across the Barrett’s disease sequence were further measured through assessment of proxy markers of cellular stress in-vitro and in-vivo. We have shown in-vitro that levels of ROS in the QH, metaplasia cell line were significantly elevated compared to other points along the Barrett’s disease sequence. The esophagus is redox-sensitive [32], but the role of oxidative stress across the Barrett’s spectrum is largely unknown. Mitochondria are the main source of ROS production, with excess levels of ROS associated with oxidative damage [33–35]. The Warburg effect theorizes cancer cells reprogram energy metabolism, reducing oxidative phosphorylation and ROS production, potentially decreasing injury to mitochondrial DNA [36, 37]; perhaps this may explain the significant reductions in ROS in our in-vitro model between the QH metaplastic cells and the Go and OE33 cells. The role of ROS as a precursor for cancer progression has been studied in many cancers. In breast cancer, BRCA-1, a tumor suppressor gene, has been shown to play a role in protecting against ROS damage; BRCA-1 mutations have subsequently been implicated in loss of redox balance with increased ROS, and may potentially drive cancer development [38].

Studies have shown that the gene cytoglobin, CYGB, is associated with ROS levels and induced in response to oxidative stress where it can try to act to scavenge excess ROS [20–22]. We have shown that CYGB was over-expressed in SIM compared to levels detected in normal, LGD and EAC tissue, supporting the concept that Barrett’s metaplasia is an environment of oxidative stress, and the pre-neoplastic tissue maybe more susceptible to oxidative damage compared to neoplastic tissue similar to what has been documented in the prostate [39]. Other studies have shown that CYGB overexpression in-vitro can induce protection from chemically-induced oxidative stress but this is only seen at non-physiological concentrations of cytoglobin [19]. Loss of CYGB expression in the latter stages of the disease potentially may reflect the inability to regulate oxidative stress, and loss of protection once tumor growth is firmly established [19, 40].

As it is not possible to assess the active secretion of mitochondrial and inflammatory proteins in fixed tissue, using an ex-vivo explant model, we assessed the secretion of mitochondrial proteins in metaplastic tissues, as the greatest levels of instability and cellular stress were observed at this pathological stage, and compared it to matched normal mucosa. The explant model system is superior to monolayer cell cultures as it encompasses
the tissue microenvironment [41]. Ex-vivo studies demonstrated a significant increase in cytochrome c and SMAC/Diablo, pro-apoptotic mitochondrial proteins in SIM tissue compared with matched normal tissue, patterns previously seen in esophageal cancer cell lines [42]. The mitochondria play a critical role in cell apoptosis. Cytochrome c and SMAC/Diablo are apoptotic proteins, released into the cytosol in order to activate a series of caspases downstream. These findings suggest an increase in mitochondrial biogenesis at the Barrett's metaplastic stage. Mitochondria have an important role in pro-inflammatory signalling; similarly, pro-inflammatory mediators may also alter mitochondrial function. In parallel with increases in mitochondrial protein secretion from metaplastic tissue, there were increases in inflammatory cytokines, IL-1β, IL-6, IL-8 and TNF-α. This complements previous observations from our group demonstrating associations between inflammation and mitochondrial instability in another inflammatory condition [43]. These data reinforce the finding that mitochondrial instability, oxidative stress and inflammatory changes are early events in the Barrett’s disease sequence. Strategies aimed at targeting these processes may represent preventive and therapeutic interventions.

**Conclusions**

We have shown that mitochondrial instability, oxidative stress and increases in mitochondrial and inflammatory protein production are activated early in the Barrett’s disease progression sequence. Although unclear whether mitochondrial dysfunction is the cause or consequence of these events, this study shows that SIM occurs in an environment of increased oxidative stress and mitochondrial instability.

**Abbreviations**

ATCC, American type culture collection; BEBM, bronchial epithelial cell basal media; CYP2C, cytoglobin; EAC, esophageal adenocarcinoma; FCS, foetal calf serum; HGD, high grade dysplasia; IL, interleukin; LGD, low grade dysplasia; RMC, random mutation capture; ROS, reactive oxygen species; RPMI, Roswell Park Memorial Institute.

---

**Fig. 5** a-f Mitochondrial proteins and inflammatory cytokines levels in explant cultured media in SIM tissue and surrounding matched-normal tissue. Wilcoxon matched-pairs signed rank tests demonstrated significantly increased levels of a cytochrome c (n=12), b SMAC/Diablo (n=8), c IL-1beta (n=12), d IL-6 (n=12), e IL-8 (n=12) and f TNF-alpha (n=12) in SIM tissue compared to surrounding normal epithelium. *p ≤ 0.05, **p ≤ 0.005 and ***p ≤ 0.0005
Children

All patients provided informed written consent, and approval for this study was obtained from the College Dublin, St. James's Hospital Institutional Ethics Review Board. Biobanking of tissue samples was supported by the Oesophageal Cancer Fund.

Availability of data and materials

The datasets supporting the conclusions of this article are included within the article. Any request of data and material may be sent to the corresponding author.

Authors’ contributions

NIJO was involved in experimental design, experimental procedures and protocols, study analysis, result interpretation and was lead author in the manuscript write-up. RF, SLP, SAWG and JIP collected patient samples, patient data and performed experimental procedures. NLL and MB were involved in experimental design, data interpretation and critique. FMcC designed the study and interpreted results. All authors have read and approved the manuscript for publication.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

All patients provided informed written consent, and approval for this study was granted by the St. James’s Hospital and Adelaide, Meath and National Children’s Hospital Institutional Ethics Review Board.

Author details

1Trinity Translational Medicine Institute, Department of Surgery, Trinity College Dublin, St. James’s Hospital, Dublin 8, Ireland. Education and Research Centre, St. Vincent’s University Hospital, Elm Park, Dublin 4, Ireland.

2Trinity Translational Medicine Institute, Department of Clinical Medicine, Trinity College Dublin, St. James’s Hospital, Dublin 8, Ireland. Department of Pathology, University of Washington, Seattle, WA 98195, USA.

Received: 23 January 2016 Accepted: 11 July 2016

Published online: 19 July 2016

References

1. Jankowski JA, Perry I, Harrison RF. Gastro-oesophageal cancer: death at the junction. BMJ. 2000;321(7259):463–4.

2. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003;349(23):2241–2249.

3. Blot WJ, Devesa SS, Kneller RW, Fraumeni Jr JF. Rising incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med. 2002;347(15):1165–1171.

4. Kohonen M, Melén E, Portin H, Aikou T, Hoelscher AH. Mutations in the mitochondrial DNA D-Loop region occur frequently in adenocarcinoma in Barrett’s esophagus. Oncogene. 2002;21(23):3780–3.

5. Loeb LA, Bielas JH, Beckman RA. Cancers exhibit a mutator phenotype: clinical implications. Cancer Res. 2008;68(10):3551–7. Discussion 3557.

6. Wallace DC. Diseases of the mitochondrial DNA. Annu Rev Biochem. 1992;61:1175–212.

7. Warburg O. On respiratory impairment in cancer cells. Science. 1956;124(3215):269–70.

8. Bensinger SJ, Christofk HR. New aspects of the Warburg effect in cancer cell biology. Semin Cell Dev Biol. 2012;23(4):352–61.

9. Koppens WH, Bounds PL, Dang CV. Otto Warburg’s contributions to current concepts of cancer metabolism. Nat Rev Cancer. 2011;11(5):325–37.

10. Putignani L, Raffa S, Pesceolodido R, Aimati L, Signore F, Torrisi MR, Grammatico P. Alteration of expression levels of the oxidative phosphorylation system (OXPHOS) in breast cancer cell mitochondria. Breast Cancer Res Treat. 2008;110(3):439–52.

11. Koemer G. Mitochondria in cancer. Oncogene. 2006;25(34):4630–2.

12. Chatterjee A, Mambo E, Sidransky D. Mitochondrial DNA mutations in human cancer. Oncogene. 2006;25(34):4663–74.

13. Miyazono F, Schneider PM, Metzger R, Warnecke-Eberz U, Baldus SE, Dienes HP, Akou T, Hoelscher AH. Mutations in the mitochondrial DNA D-Loop region occur frequently in adenocarcinoma in Barrett’s esophagus. Oncogene. 2002;21(23):3780–3.

14. Fordel E, Thijis L, Martinet W, Lenjou M, Laufs T, Van Bockstaele D, Moens L, Dewilde S. Neuroglobin and cytoglobin overexpression protects human SH-SYSY neuroblastoma cells against oxidative stress-induced cell death. Neurosci Lett. 2006;402(2):146–51.

15. King A, Selak MA, Gottlieb E. Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer. Oncogene. 2006;25(34):4675–82.

16. Robey RB, Hay N. Mitochondrial hexokinases, novel mediators of the ant apoptotic effects of growth factors and Akt. Oncogene. 2006;25(34):4683–96.

17. Wallace DC. A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. Annu Rev Genet. 2005;39:359–407.

18. Gorman S, Fox E, O’Donoghue D, Sheehan K, Hyland J, Mulcahy H, Loeb LA, O’Sullivan J. Mitochondrial mutagenesis induced by tumor-specific radiation bystander effects. J Mol Med. 2010;88(7):701–8.

19. Goldsby RE, Lawrence NA, Olmsted EA, Chen X, Singh M, Preston BD. DNA polymerase epsilon and delta contribute to the mutator phenotype in cancer. Proc Natl Acad Sci U S A. 2003;100(3):1165–70.

20. Albertson TM, Ogawa M, Bugni JM, Hays LE, Yount PA, Parry JM, Griffiths PA, Baxter JN. Deoxycholic acid at neutral and acid pH is genotoxic to oesophageal cells through the induction of ROS. The potential role of anti-oxidants in Barrett’s oesophagus. Carcinogenesis. 2007;28(11):136–42.

21. Hvid-Jensen F, Pedersen L, Sorensen HT, Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett’s esophagus. Eur J Med. 2011;136(5):1375–83.

22. King A, Selak MA, Gottlieb E. Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer. Oncogene. 2006;25(34):4675–82.

23. King A, Selak MA, Gottlieb E. Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer. Oncogene. 2006;25(34):4675–82.

24. Robey RB, Hay N. Mitochondrial hexokinases, novel mediators of the ant apoptotic effects of growth factors and Akt. Oncogene. 2006;25(34):4683–96.

25. Wallace DC. A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. Annu Rev Genet. 2005;39:359–407.

26. Loeb LA, Mutator phenotype in cancer: origin and consequences. Semin Cancer Biol. 2010;20(5):279–80.

27. Albertson TM, Ogawa M, Bugni JM, Hays LE, Chen Y, Wang Y, Treuting PM, Heddie JA, Goldsby RE, Preston BD. DNA polymerase epsilon and delta proofreading suppress discrete mutator and cancer phenotypes in mice. Nat Genet. 2006;38(4):410–414.

28. Goldsby RE, Lawrence NA, Hays LE, Oltmstead EA, Chen Y, Singh M, Preston BD. Defective DNA polymerase-delta proofreading causes cancer susceptibility in mice. Nat Med. 2001;7(6):638–9.

29. Tuppen HA, Blakeley EL, Turnbull DM, Taylor RW. Mitochondrial DNA mutations and human disease. Biochim Biophys Acta. 2011;1797(3):113–28.

30. Ericson NG, Kulawiec M, Vermulst M, Sheahan K, O’Brien P, O’Keeffe E, Mulcahy H, Loeb LA. Mitochondrial DNA and cancer: a dawn for evolutionary medicine. Annu Rev Genet. 2012;46:355–78.

31. Albertson TM, Ogawa M, Bugni JM, Hays LE, Chen Y, Wang Y, Treuting PM, Heddie JA, Goldsby RE, Preston BD. DNA polymerase epsilon and delta proofreading suppress discrete mutator and cancer phenotypes in mice. Nat Genet. 2006;38(4):410–414.
35. Moriya M. Single-stranded shuttle phagemid for mutagenesis studies in mammalian cells: 8-oxoguanine in DNA induces targeted G.C→T.A transversions in simian kidney cells. Proc Natl Acad Sci U S A. 1993; 90(3): 1122–1126.
36. Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309–14.
37. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009; 324(5930):1029–33.
38. Acharya A, Das I, Chandhok D, Saha T. Redox regulation in cancer: a double-edged sword with therapeutic potential. Oxid Med Cell Longev. 2010;3(1):23–34.
39. Mogal AP, Watson MA, Ozsolak F, Salavaggione L, Humphrey PA. Gene expression profiles and differential cytoglobin expression in atrophy and adenocarcinoma of the prostate. Prostate. 2012;72(9):931–7.
40. McRonald FE, Liloglou T, Xinarianos G, Hill L, Rovbottom L, Langan JE, Ellis A, Shaw JM, Field JK, Risk JM. Down-regulation of the cytoglobin gene, located on 17q25, in tylosis with oesophageal cancer (TOC): evidence for trans-allele repression. Hum Mol Genet. 2006;15(8):1271–7.
41. Gorman S, Tosetto M, Lyng F, Howe O, Sheahan K, O’Donoghue D, Hyland J, Mulcahy H, O’Sullivan J. Radiation and chemotherapy bystander effects induce early genomic instability events: telomere shortening and bridge formation coupled with mitochondrial dysfunction. Mutat Res. 2009;669(1–2):131–8.
42. Aggarwal S, Taneja N, Lin L, Orringer MB, Rehemtulla A, Beer DG. Indomethacin-induced apoptosis in esophageal adenocarcinoma cells involves upregulation of Bax and translocation of mitochondrial cytochrome C independent of COX-2 expression. Neoplasia. 2000;2(4):346–56.
43. Biniecka M, Kennedy A, Ng CT, Chang TC, Balogh E, Fox E, Veale DJ, Fearon U, O’Sullivan JN. Successful tumour necrosis factor (TNF) blocking therapy suppresses oxidative stress and hypoxia-induced mitochondrial mutagenesis in inflammatory arthritis. Arthritis Res Ther. 2011;13(4):R121.